Related Experiment Video

Updated: Mar 18, 2026

Isolated Pancreatic Islet Treatment and Apoptosis Measurement
09:36

Isolated Pancreatic Islet Treatment and Apoptosis Measurement

Published on: May 2, 2025

1000

High-dose atorvastatin is associated with lower IGF-1 levels in patients with type 1 diabetes

Karin Bergen1, Kerstin Brismar2, Sara Tehrani1

  • 1Karolinska Institutet, Department of Clinical Sciences Danderyd Hospital, Division of Internal Medicine, Danderyd Hospital, 182 88 Stockholm, Sweden.

Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society
|July 12, 2016
PubMed

Insights

High-dose atorvastatin significantly decreased insulin-like growth factor 1 (IGF-1) levels in type 1 diabetes patients. This reduction may negatively impact microvascular function and increase long-term microangiopathy risk.

Area of Science:

  • Endocrinology
  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Insulin-like growth factor 1 (IGF-1) and IGFBP-1 are crucial for vascular health.
  • Statins are commonly used in type 1 diabetes to prevent vascular complications.
  • The impact of statins on the IGF-1/IGFBP-1 axis in these patients is not well understood.

Purpose of the Study:

  • To investigate the effect of atorvastatin on IGF-1 and IGFBP-1 levels.
  • To assess the relationship between atorvastatin, IGF-1/IGFBP-1 axis, and microvascular function in type 1 diabetes.

Main Methods:

  • A double-blinded, cross-over study involving 20 type 1 diabetes patients.
  • Patients received 80mg atorvastatin or placebo for two months.
  • IGF-1, IGFBP-1 levels, and skin microvascular reactivity were measured.

Main Results:

  • High-dose atorvastatin significantly reduced IGF-1 levels compared to placebo (p<0.05).
  • No significant effect of atorvastatin was observed on IGFBP-1 or the IGF-1/IGFBP-1 ratio.
  • IGF-1/IGFBP-1 levels did not correlate with microvascular reactivity measurements.

Conclusions:

  • Atorvastatin treatment is associated with decreased IGF-1 levels in type 1 diabetes.
  • This reduction may suggest a potential adverse effect on microvascular function.
  • Further research is needed to understand the long-term implications for microangiopathy risk.
Abstract

Keywords:
HMG-CoA reductase inhibitorsIGF-1IGFBP-1Insulin-like growth factor 1Insulin-like growth factor binding protein 1MicrocirculationStatinsType 1 diabetes

More Related Videos

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health06:13

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Published on: December 1, 2023

1.8K
Lentiviral Mediated Gene Silencing in Human Pseudoislet Prepared in Low Attachment Plates11:24

Lentiviral Mediated Gene Silencing in Human Pseudoislet Prepared in Low Attachment Plates

Published on: May 14, 2019

5.9K

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.8K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.1K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
934
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.4K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
830
Oral Hypoglycemic Agents: &#945;-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
808